<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02060019</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_EXR_101</org_study_id>
    <nct_id>NCT02060019</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects</brief_title>
  <official_title>A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designated to evaluate the pharmacokinetic interactions of amlodipine besylate,&#xD;
      valsartan and rosuvastatin in healthy male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the drug-drug interactions of amlodipine, valsartan and rosuvastatin: Cmax,ss(Maximum steady-state plasma drug concentration during a dosage interval ), AUCτ(Area Under the Curve)</measure>
    <time_frame>3 days</time_frame>
    <description>after steady state (Administration of Investigational Product 7day or 10days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the amlodipine, valsartan and rosuvastatin : AUCinf, tmax,ss(Time to reach Cmax,ss), t1/2</measure>
    <time_frame>3 days</time_frame>
    <description>steady state (Administration of Investigational Product)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>exforge 10/160mg(amlodipine 10mg, valsartan160mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet daily for 10days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>crestor 20mg(rosuvastatin 20mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet daily for 7days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.</intervention_name>
    <arm_group_label>crestor 20mg(rosuvastatin 20mg)</arm_group_label>
    <arm_group_label>exforge 10/160mg(amlodipine 10mg, valsartan160mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male volunteers in the age between 20 and 55 years old&#xD;
&#xD;
          2. The weight range is not exceed ±20% of ideal weight Ideal weight = [height -100]*0.9&#xD;
&#xD;
          3. Subjects with no history of any significant chronic disease&#xD;
&#xD;
          4. Judged to be in good health on the basis of their electrocardiography (ECG) and&#xD;
             routine laboratory data obtained within 3 weeks prior to study drug administration&#xD;
&#xD;
          5. Willing to adhere to protocol requirements and sign a informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of clinically significant allergies including drug allergies&#xD;
&#xD;
          2. History of clinically significant hepatic, renal, gastrointestinal, pulmonary,&#xD;
             ,musculoskeletal, endocrine, psychiatric, hematologic, oncologic, neurologic or&#xD;
             cardiovascular disease&#xD;
&#xD;
          3. History of genetic muscular disease and family history&#xD;
&#xD;
          4. hypotension (Systolic Blood Pressure(SBP) ≤ 105 or Diastolic Blood Pressure(DBP) ≤ 65)&#xD;
             or hypertension(SBP ≥ 150 or DBP ≥ 100)&#xD;
&#xD;
          5. AST(Aspartate Transaminase), ALT(ALanine Transaminase), total bilirubin( &gt; 1.5 times&#xD;
             to normal range&#xD;
&#xD;
          6. Creatinine clearance &lt; 80mL/min&#xD;
&#xD;
          7. Subjects with a history of gastrointestinal diseases which might significantly change&#xD;
             ADME(Absorption, Distribution, Metabolism and Excretion) of medicines&#xD;
&#xD;
          8. Serious injury, surgery and acute illness within 4 weeks prior to drug administration&#xD;
&#xD;
          9. History of alcohol, smoking abuse&#xD;
&#xD;
               -  alcohol &gt; 21 units/week, 1 unit=10g=12.5mL of pure alcohol&#xD;
&#xD;
               -  smoking &gt; 10 cigarettes/day&#xD;
&#xD;
         10. Use of any other medication, including herbal products, within the 2 weeks before&#xD;
             dosing&#xD;
&#xD;
         11. Participated in a previous clinical trial within 3 months prior to drug administration&#xD;
&#xD;
         12. Subjects with whole blood donation within 2 months, component blood donation within&#xD;
             months prior to drug administration&#xD;
&#xD;
         13. Special diet known to interfere with the absorption, distribution, metabolism or&#xD;
             excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior&#xD;
             to drug administration&#xD;
&#xD;
         14. Clinical laboratory test values are positive (HBsAg, HCV Ab, HIV Ag/Ab, VDRL)&#xD;
&#xD;
         15. Subjects considered as unsuitable based on medical judgement by investigators&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Ran Yoon PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook university hostipal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyungpook university hospital</name>
      <address>
        <city>Deagu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>February 6, 2014</study_first_submitted>
  <study_first_submitted_qc>February 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

